Literature DB >> 22404717

Opioid detoxification and naltrexone induction strategies: recommendations for clinical practice.

Stacey C Sigmon1, Adam Bisaga, Edward V Nunes, Patrick G O'Connor, Thomas Kosten, George Woody.   

Abstract

BACKGROUND: Opioid dependence is a significant public health problem associated with high risk for relapse if treatment is not ongoing. While maintenance on opioid agonists (i.e., methadone, buprenorphine) often produces favorable outcomes, detoxification followed by treatment with the μ-opioid receptor antagonist naltrexone may offer a potentially useful alternative to agonist maintenance for some patients.
METHOD: Treatment approaches for making this transition are described here based on a literature review and solicitation of opinions from several expert clinicians and scientists regarding patient selection, level of care, and detoxification strategies.
CONCLUSION: Among the current detoxification regimens, the available clinical and scientific data suggest that the best approach may be using an initial 2-4 mg dose of buprenorphine combined with clonidine, other ancillary medications, and progressively increasing doses of oral naltrexone over 3-5 days up to the target dose of naltrexone. However, more research is needed to empirically validate the best approach for making this transition.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22404717      PMCID: PMC4331107          DOI: 10.3109/00952990.2011.653426

Source DB:  PubMed          Journal:  Am J Drug Alcohol Abuse        ISSN: 0095-2990            Impact factor:   3.829


  89 in total

1.  Improvement in naltrexone treatment compliance with contingency management.

Authors:  K L Preston; K Silverman; A Umbricht; A DeJesus; I D Montoya; C R Schuster
Journal:  Drug Alcohol Depend       Date:  1999-04-01       Impact factor: 4.492

2.  Predictors and prevention of nonfatal overdose among street-recruited injection heroin users in the San Francisco Bay Area, 1998-1999.

Authors:  K H Seal; A H Kral; L Gee; L D Moore; R N Bluthenthal; J Lorvick; B R Edlin
Journal:  Am J Public Health       Date:  2001-11       Impact factor: 9.308

3.  Contingency management to enhance naltrexone treatment of opioid dependence: a randomized clinical trial of reinforcement magnitude.

Authors:  Kathleen M Carroll; Rajita Sinha; Charla Nich; Theresa Babuscio; Bruce J Rounsaville
Journal:  Exp Clin Psychopharmacol       Date:  2002-02       Impact factor: 3.157

4.  Network therapy for addiction: bringing family and peer support into office practice.

Authors:  M Galanter; D Brook
Journal:  Int J Group Psychother       Date:  2001-01

5.  Ultrarapid opioid detoxification: effects on cardiopulmonary physiology, stress hormones and clinical outcomes.

Authors:  I Elman; M N D'Ambra; S Krause; H Breiter; M Kane; R Morris; L Tuffy; D R Gastfriend
Journal:  Drug Alcohol Depend       Date:  2001-01-01       Impact factor: 4.492

6.  Naltrexone shortened opioid detoxification with buprenorphine.

Authors:  A Umbricht; I D Montoya; D R Hoover; K L Demuth; C T Chiang; K L Preston
Journal:  Drug Alcohol Depend       Date:  1999-10-01       Impact factor: 4.492

7.  Opiate detoxification under anesthesia: no apparent benefit but suppression of thyroid hormones and risk of pulmonary and renal failure.

Authors:  R Pfab; C Hirtl; T Zilker
Journal:  J Toxicol Clin Toxicol       Date:  1999

8.  Heroin-related deaths in New South Wales, Australia, 1992-1996.

Authors:  S Darke; J Ross; D Zador; S Sunjic
Journal:  Drug Alcohol Depend       Date:  2000-08-01       Impact factor: 4.492

9.  Complications of ultrarapid opioid detoxification with subcutaneous naltrexone pellets.

Authors:  Richard J Hamilton; Ruben E Olmedo; Sachin Shah; Oliver L Hung; Mary Ann Howland; Jeanmarie Perrone; Lewis S Nelson; Neal L Lewin; Robert S Hoffman
Journal:  Acad Emerg Med       Date:  2002-01       Impact factor: 3.451

10.  A 33-year follow-up of narcotics addicts.

Authors:  Y I Hser; V Hoffman; C E Grella; M D Anglin
Journal:  Arch Gen Psychiatry       Date:  2001-05
View more
  33 in total

1.  A placebo-controlled trial of memantine as an adjunct to injectable extended-release naltrexone for opioid dependence.

Authors:  Adam Bisaga; Maria A Sullivan; Andrew Glass; Kaitlyn Mishlen; Kenneth M Carpenter; John J Mariani; Frances R Levin; Edward V Nunes
Journal:  J Subst Abuse Treat       Date:  2014-01-17

2.  Long-Acting Injectable Naltrexone Induction: A Randomized Trial of Outpatient Opioid Detoxification With Naltrexone Versus Buprenorphine.

Authors:  Maria Sullivan; Adam Bisaga; Martina Pavlicova; C Jean Choi; Kaitlyn Mishlen; Kenneth M Carpenter; Frances R Levin; Elias Dakwar; John J Mariani; Edward V Nunes
Journal:  Am J Psychiatry       Date:  2017-01-10       Impact factor: 18.112

3.  Clonidine Maintenance Prolongs Opioid Abstinence and Decouples Stress From Craving in Daily Life: A Randomized Controlled Trial With Ecological Momentary Assessment.

Authors:  William J Kowalczyk; Karran A Phillips; Michelle L Jobes; Ashley P Kennedy; Udi E Ghitza; Daniel A Agage; John P Schmittner; David H Epstein; Kenzie L Preston
Journal:  Am J Psychiatry       Date:  2015-03-17       Impact factor: 18.112

4.  Extended release naltrexone injection is performed in the majority of opioid dependent patients receiving outpatient induction: a very low dose naltrexone and buprenorphine open label trial.

Authors:  Paolo Mannelli; Li-Tzy Wu; Kathleen S Peindl; Marvin S Swartz; George E Woody
Journal:  Drug Alcohol Depend       Date:  2014-02-15       Impact factor: 4.492

5.  Replication of an emergency department-based recovery coaching intervention and pilot testing of pragmatic trial protocols within the context of Indiana's Opioid State Targeted Response plan.

Authors:  Dennis P Watson; Krista Brucker; Alan McGuire; Nyssa L Snow-Hill; Huiping Xu; Alex Cohen; Mark Campbell; Lisa Robison; Emily Sightes; Rebecca Buhner; Daniel O'Donnell; Jeffrey A Kline
Journal:  J Subst Abuse Treat       Date:  2019-06-06

6.  The effects of dronabinol during detoxification and the initiation of treatment with extended release naltrexone.

Authors:  Adam Bisaga; Maria A Sullivan; Andrew Glass; Kaitlyn Mishlen; Martina Pavlicova; Margaret Haney; Wilfrid N Raby; Frances R Levin; Kenneth M Carpenter; John J Mariani; Edward V Nunes
Journal:  Drug Alcohol Depend       Date:  2015-07-08       Impact factor: 4.492

Review 7.  New directions in the treatment of opioid withdrawal.

Authors:  A Benjamin Srivastava; John J Mariani; Frances R Levin
Journal:  Lancet       Date:  2020-06-20       Impact factor: 79.321

8.  NIDA Clinical Trials Network CTN-0051, Extended-Release Naltrexone vs. Buprenorphine for Opioid Treatment (X:BOT): Study design and rationale.

Authors:  Joshua D Lee; Edward V Nunes; Patricia Novo Mpa; Genie L Bailey; Gregory S Brigham; Allan J Cohen; Marc Fishman; Walter Ling; Robert Lindblad; Dikla Shmueli-Blumberg; Don Stablein; Jeanine May; Dagmar Salazar; David Liu; John Rotrosen
Journal:  Contemp Clin Trials       Date:  2016-08-10       Impact factor: 2.226

9.  Decreased injecting is associated with increased alcohol consumption among injecting drug users in northern Vietnam.

Authors:  Vivian F Go; Nguyen Le Minh; Constantine Frangakis; Tran Viet Ha; Carl A Latkin; Teerada Sripaipan; Wendy Davis; Carla Zelaya; Nguyen Phuong Ngoc; Vu Minh Quan
Journal:  Int J Drug Policy       Date:  2013-01-17

Review 10.  Prescription Opioid Misuse, Abuse, and Treatment in the United States: An Update.

Authors:  Kathleen T Brady; Jenna L McCauley; Sudie E Back
Journal:  Am J Psychiatry       Date:  2015-09-04       Impact factor: 18.112

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.